Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ulotaront in Schizophrenia (Japan)
NCT05359081Phase 3Terminated
- Sponsor
- Sumitomo Pharma
- Start
- May 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Sumitomo Pharma. Started May 2022; status: terminated.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05359081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359081.